Ex Parte LI et al - Page 4



              Appeal No. 2003-1020                                                           Page 4                        
              Application No. 08/859,051                                                                                   

                     Mezei describes the relative activities of two different preparations of                              
              triamcinolone: 0.1% triamcinolone in “ointment dosage form,” and a liposomal                                 
              preparation of 0.1% triamcinolone free of unencapsulated triamcinolone.  According to                        
              Mezei, “liposomal encapsulation favorably altered [triamcinolone] deposition; the                            
              greatest changes occurred in the target tissue, and at the sites where toxic actions are                     
              localized.”  “[P]ercutaneous absorption was greatly reduced, while at the same time, the                     
              concentration of the drug was significantly increased at the site (i.e., epidermis and                       
              dermis), where its activity is desired” (page 1474).  Thus, “the presently accepted                          
              therapeutic concentration can be achieved by a four-fold reduction in the dose . . .                         
              [which] would lead to . . . an additional decrease in unwanted systemic effects” (pages                      
              1475-1476).                                                                                                  
                     du Plessis teaches that “the deposition of [a topically administered liposome-                        
              encapsulated] drug into the living epidermis and/or dermis cannot be predicted by                            
              determination of the amount of drug in the total skin” as “[t]he amounts in the deeper                       
              skin strata were also in the order of increasing number of follicles/hair in the skin                        
              species, suggesting that the transfollicular route is an important pathway for liposomal                     
              topical therapeutics” (Abstract, page 259).  That is, “liposomal drug transport into strata                  
              below and beyond the stratum corneum may occur via a follicular route” (page 263).2                          
                     According to the examiner, “[i]t is unclear from . . . Bonte and Rössling whether                     
              the unencapsulated active agent was removed,” but “[o]ne skilled in the art would be                         
              motivated to remove the [un]encapsulated material if it is detrimental since [ ] Mezei                       
              teaches that [un]encapsulated material can be removed by chromatography” and “[o]ne                          


                     2 The stratum corneum is the outer layer of the epidermis, consisting of several                      
              layers of flat keratinized non-nucleated cells.  Stedman’s Medical Dictionary, Illustrated,                  
              24th Edition, Williams & Wilkins, Baltimore/London, page 1347 (1982).                                        

Page:  Previous  1  2  3  4  5  6  7  8  Next 

Last modified: November 3, 2007